Publications by authors named "Rubin Lubomirov"

Claim this Profile
C
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin.
Rubin Lubomirov, Laura Pérez-Ramos, Salvador Fudio, Eduardo Asín-Prieto, Laura Ibarra-Gómez

Clin Transl Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Description and Modeling of Relevant Demographic and Laboratory Variables in a Large Oncology Cohort to Generate Virtual Populations.
Laura Pérez-Ramos, Laura Ibarra-Gómez, Rubin Lubomirov, María García-Cremades, Eduardo Asín-Prieto

Pharmaceutics· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Rubin Lubomirov

Mar Drugs· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study.
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Rubin Lubomirov

Pharmaceuticals (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.
Salvador Fudio, Laura Pérez-Ramos, Eduardo Asín-Prieto, Ali Zeaiter, Rubin Lubomirov

Front Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS.
Nicholas King, Soledad Garcia-Martinez, Eider Alcaraz, Alba Grisalena, Rubin Lubomirov

PLoS One· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics.
Salvador Fudio, Alvaro Sellers, Laura Pérez Ramos, Beatriz Gil-Alberdi, Ali Zeaiter, Rubin Lubomirov

Cancer Chemother Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
Carlos Fernández-Teruel, Salvador Fudio, Rubin Lubomirov

Cancer Chemother Pharmacol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
Jose F Varona, Pedro Landete, Jose A Lopez-Martin, Vicente Estrada, Roger Paredes, Rubin Lubomirov

Life Sci Alliance· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
Carlos Fernández-Teruel, Rubin Lubomirov, Salvador Fudio

J Clin Pharmacol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.
José F Varona, Pedro Landete, Jose A Lopez-Martin, Vicente Estrada, Roger Paredes, Rubin Lubomirov

medRxiv· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Salvador Fudio, Josep Tabernero, Vivek Subbiah, Sant P Chawla, Victor Moreno, Rubin Lubomirov

Cancer Chemother Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.
Carlos Fernandez-Teruel, Ignacio Gonzalez, Iñaki F Trocóniz, Rubin Lubomirov, Arturo Soto

Clin Pharmacokinet· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects.
Dora Koller, Carmen Belmonte, Rubin Lubomirov, Miriam Saiz-Rodríguez, Pablo Zubiaur

J Psychopharmacol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.
Anaïs Glatard, Maria Dobrinas, Mehdi Gholamrezaee, Rubin Lubomirov, Jacques Cornuz

Exp Clin Psychopharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of two variants of CYP450 oxidoreductase on the stable dose of acenocoumarol in a Spanish population.
Hoi Y Tong, Alberto M Borobia, José Carlos Martínez Ávila, Rubin Lubomirov, Mario Muñoz

Pharmacogenomics· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population.
Hoi Y Tong, Cristina Lucía Dávila-Fajardo, Alberto M Borobia, Luis Javier Martínez-González, Rubin Lubomirov

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited sampling strategies for tacrolimus exposure (AUC0-24) prediction after Prograf(®) and Advagraf(®) administration in children and adolescents with liver or kidney transplants.
Gonzalo N Almeida-Paulo, Rubin Lubomirov, Nazareth Laura Alonso-Sanchez, Laura Espinosa-Román, Carlota Fernández Camblor

Transpl Int· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.
Margalida Rotger, Tracy R Glass, Thomas Junier, Jens Lundgren, James D Neaton, Rubin Lubomirov

Clin Infect Dis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.
Alberto M Borobia, Rubin Lubomirov, Elena Ramírez, Alicia Lorenzo, Armando Campos

PLoS One· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Maria Dobrinas, Séverine Crettol, Beatrice Oneda, Rachel Lahyani, Margalida Rotger, Rubin Lubomirov

Pharmacogenet Genomics· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Rubin Lubomirov, Mona Arab-Alameddine, Margalida Rotger, Aurélie Fayet-Mello, Raquel Martinez

Pharmacogenet Genomics· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery.
Adelina Pellicer, Joan Riera, Paloma Lopez-Ortego, María Carmen Bravo, Rosario Madero, Rubin Lubomirov

Pediatr Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Mona Arab-Alameddine, Aurélie Fayet-Mello, Rubin Lubomirov, Michael Neely, Julia di Iulio

Antimicrob Agents Chemother· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.
Rubin Lubomirov, Sara Colombo, Julia di Iulio, Bruno Ledergerber, Raquel Martinez

J Infect Dis· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis